Seronegative nonparaneoplastic Lambert—Eaton myasthenic syndrome

Sanadze A.G.; Sidnev D.V.; Tumurov D.A.

doi:https://doi.org/10.17116/jnevro20171175177-80

Sanadze A.G.

GKB #51, Moskovskiĭ miastenicheskiĭ tsentr

Sidnev D.V.

GKB #51, Moskovskiĭ miastenicheskiĭ tsentr

Tumurov D.A.

Moscow City Health Department, Moscow Myasthenia Center, SFHI Municipal Clinical Hospital No. 51, Moscow, Russia;
Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia

Seronegative nonparaneoplastic Lambert—Eaton myasthenic syndrome

Authors:

Sanadze A.G., Sidnev D.V., Tumurov D.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5): 77‑80

DOI: 10.17116/jnevro20171175177-80

Read: 9874 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Sanadze AG, Sidnev DV, Tumurov DA. Seronegative nonparaneoplastic Lambert—Eaton myasthenic syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(5):77‑80. (In Russ.)
https://doi.org/10.17116/jnevro20171175177-80

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)

Использование инфографики авторами научных работ

Close metadata

Abstract:

The authors studied two patients with Lambert—Eaton myasthenic syndrome (LEMS) in whom the repeated examination did not find specific of LEMS P/Q type voltage-gates calcium channel autoantibodies. The results of clinical testing and electrophysiological examination showed the typical character of movement disorders with the absence of tendon reflexes and signs of disautonomia as well as a decrease in M-response amplitude and phenomena of decrement with low frequency- and increment with high frequency stimulation. Both patients revealed no signs of paraneoplastic process. Autoimmune character of the damage was confirmed by the effectiveness of treatment with glucocorticoid hormones.

Keywords:

Lambert—Eaton myasthenic syndrome (LEMS)

voltage-gates calcium channel autoantibodies

Authors:

Sanadze A.G.

GKB #51, Moskovskiĭ miastenicheskiĭ tsentr

Sidnev D.V.

GKB #51, Moskovskiĭ miastenicheskiĭ tsentr

Tumurov D.A.

Moscow City Health Department, Moscow Myasthenia Center, SFHI Municipal Clinical Hospital No. 51, Moscow, Russia;
Moscow Research and Clinical Center for Neuropsychiatry, Moscow, Russia

Close metadata

References:

Sanadze AG. Miasteniya i miastenicheskie sindromy. M.: Litera; 2012. (In Russ.).
Sanadze AG, Sidnev DV, Karganov MYu, Shcherbakova NI. Miastenicheskii sindrom Lamberta—Itona. Nevrol i psikhiatr. 2006;3:10-14. (In Russ.).
Morimoto M, Osaki T, Nagara Y, Kodate M, Motomura M, Murai H. Thymoma with Lambert—Eaton myasthenic syndrome. Ann Thorac Surg. 2010;89(6):2001-2003. Available from: doi:10.1016/j.athoracsur.2009.11.041
Newsom-Davis J. Lambert—Eaton myasthenic syndrome. Springer semin. Immunopathol. 1985;129-140. Available from: doi:10.1007/bf00197251
O’Neill J, Murray N, Newsom-Davis J. The Lambert—Eaton myasthenic syndrome. A review of 50 cases. Brain. 1988;111:577-596. Available from: doi:10.1093/brain/111.3.577
Lang B, Pinto A, Giovannini F, Newsom-Davis J, Vincent A. Pathogenic autoantibodies in the Lambert—Eaton Myasthenic Syndrome. Ann NY Acad Sci. 2003;998:187-195. Available from: doi:10.1196/annals.1254.019
Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, Miljanich GP, Lambert EH. Calcium-channel antibodies in the Lambert—Eaton syndrome and other paraneoplastic syndromes . N Engl J Med. 1995;332:1467-1474. Available from: doi:10.1056/nejm199506013322203
Sanadze AG, Sidnev DV, Karganov MYu. Antitela k potentsialzavisimym kal'tsievym kanalam i atsetilkholinovym retseptoram u bol'nykh miastenicheskim sindromom Lamberta—Itona. Neiroimmunologiya. 2006;4:1-2:40-43. (In Russ.).
Black JL, Griesmann GE, Erickson J, Kryzer TJ, Lamke GT, Lennon VA. Lambert—Eaton myasthenic syndrome: antigenicity of recombinant human P/Q-type calcium channel {alpha}1 subunit putative ion pore region (domain IV, S5-S6). Ann NY Acad Sci. 1998;841:691-695. Available from: doi:10.1111/j.1749-6632.1998.tb11004.x
El Far O, Marqueze B, Leveque C et al. Antigens associated with N- and L-type calcium channels in Lambert—Eaton myasthenic syndrome. J Neurochem. 1995;64:1696-1702. Available from: doi:10.1046/j.1471-4159.1995.64041696.x
Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and anti-N-type calcium channel autoantibodies in the Lambert—Eaton myasthenic syndrome. J Neurol Sci. 1997;147:35-42. Available from: doi:10.1016/s0022-510x(96)05303-8
Clouston PD, Saper CB, Arbizu T et al. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurology. 1992;42:1944-1950.
Dropcho EJ, Stanton C, Oh SJ. Neuronal antinuclear antibodies in a patient with Lambert—Eaton myasthenic syndrome and small cell lung carcinoma. Neurology. 1989;39:249-251. Available from: doi:10.1212/wnl.39.2.249
Elrington GM, Murray NM, Spiro SG, Newsom-Davis J. Neurological paraneoplastic syndromes in patients with small cell lung cancer: a prospective survey of 150 patients. J Neurol Neurosurg Psychiatry. 1991;54:764-767. Available from: doi:10.1136/jnnp.54.9.764
Hajela RK, Atchison WD. The proteins synaptotagmin and syntaxin are not general targets of Lambert—Eaton myasthenic syndrome autoantibody. J Neurochem. 1995;64:1245-1251. Available from: doi:10.1046/j.1471-4159.1995.64031245.x
Takamori M, Takahashi M, Yasukawa Y et al. Antibodies to recombinant synaptotagmin and calcium channel subtypes in Lambert—Eaton myasthenic syndrome. J Neuro Sci. 1995;133:95-101. Available from: doi:10.1016/0022-510x(95)00162-u
Sher E, Codignola A, Passafaro M, Tarroni P, Magnelli V, Carbone E, Clementi F. Nicotinic receptors and calcium channels in small cell lung carcinoma: functional role, modulation, and autoimmunity. Ann NY Acad Sci. 1998;841:606-624. Available from: doi:10.1111/j.1749-6632.1998.tb10993.x
Vernino S, Low PA, Fealey RD, Stewart JD, Farrugia G, Lennon VA. Autoantibodies to Ganglionic Acetylcholine Receptors in Autoimmune Autonomic Neuropathies. N Engl J Med. 2000;343:847-855. Available from: doi:10.1056/nejm200009213431204
Sidnev DV, Karganov MYu, Shcherbakova NI, Alchinova IB, Sanadze AG. Antitela k atsetilkholinovomu retseptoru u bol'nykh s razlichnymi klinicheskimi formami miastenii i miastenicheskim sindromom Lamberta—Itona. Nevrol i psikhiatr. 2006;2:10-14. (In Russ).
Oh SJ, Sher E. MG and LEMS overlap syndrome: case report with electrophysiological and immunological evidence. Clin Neurophysiol. 2005;116:5:1167-1171. Available from: doi:10.1016/j.clinph.2004.12.013
Hajjar M, Markowitz J, Drras BT, Srinivasan J, Jones YR. Lambert-Eaton syndrome, an unrecogniztd treatable pediatric neuromuscular disorder: three patients and literature review. Pediatr Neurol. 2014;50(1):11-17. Available from: doi:10.1016/j.pediatrneurol.2013.08.009